Cigna®

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

Belrapzo, Bendeka, Treanda
(bendamustine)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		

Urgency:
☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)

Medication requested:
☐ Belrapzo 100mg/4mL solution for injection
☐ Bendamustine 100mg/4mL solution for injection
☐ Bendamustine 25mg powder for injection
☐ Bendamustine vial 100mg powder for injection
☐ Bendeka 100mg/4mL solution for injection
☐ Treanda 25mg powder for injection
☐ Treanda 100mg powder for injection

Dose: Frequency of therapy: Duration of therapy:

Is this a new start? ☐ Yes ☐ No Start date: ICD10:

(if continued therapy) How many cycles of bendamustine therapy has your patient already completed? Please note that Belrapzo, Bendeka, Treanda and Vivimusta are brand names of bendamustine. _____

How many TOTAL treatment cycles are anticipated? This includes completed cycles. ----------

Where will this medication be obtained?
☐ Accredo Specialty Pharmacy**
☐ Prescriber's office stock (billing on a medical claim form)
☐ Other (please specify):
☐ Retail pharmacy
☐ Home Health / Home Infusion vendor
***Cigna's nationally preferred specialty pharmacy*

***Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 | NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557*

Facility and/or doctor dispensing and administering medication:
Facility Name: State: Tax ID#:
Address (City, State, Zip Code):

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? ☐ Yes ☐ No

Diagnosis related to use:
☐ AIDS-Related B-Cell lymphoma (including AIDS-related diffuse large B-cell lymphoma, primary effusion lymphoma and lymphoma associated with Castleman's disease)
☐ adult T-cell leukemia/lymphoma (ATLL)
☐ angioimmunoblastic T-cell lymphoma (immunoblastic lymphadenopathy, AITL)
☐ primary cutaneous anaplastic large cell lymphoma (pcALCL)
☐ systemic anaplastic large cell lymphoma (sALCL)
☐ chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
☐ diffuse large B-Cell lymphoma (DLBCL)

☐ Extranodal Marginal Zone Lymphoma of Nongastric Sites (Noncutaneous)
☐ Extranodal Marginal Zone Lymphoma of the Stomach
☐ follicular lymphoma (FL)
☐ gastric MALT lymphoma
☐ Hematopoietic Cell Transplantation
☐ hepatosplenic gamma-delta T-cell lymphoma (HSGDTCL)
☐ high-grade B-cell lymphoma
☐ histologic transformation from marginal zone lymphoma (MZL) to diffuse large B-cell lymphoma (DLBCL)
☐ Hodgkin lymphoma (HL)
☐ mantle cell lymphoma (MCL)
☐ multiple myeloma (MM)
☐ mycosis fungoides/Sezary syndrome (MF,SS)
☐ nodal marginal zone lymphoma (NMZL)
☐ non-gastric MALT lymphoma
☐ peripheral T-cell lymphoma (PTCL)
☐ post-transplant lymphoproliferative disorder (PTLD)
☐ small cell lung cancer (SCLC)
☐ splenic marginal zone lymphoma (SMZL)
☐ Systemic Light Chain Amyloidosis
☐ Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma
☐ Other (please specify):

Clinical Questions:

What is your patient's height? _____cm/in (circle unit of measure)

What is your patient's weight?_____ kg/lb (circle unit of measure)

(if AIDS-related B-cell lymphoma) Does your patient have relapsed disease? ☐ Yes ☐ No

(if CLL/SLL) Will/Is the requested medication being used in combination with Zydelig (idelaisib) and rituximab (Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima)? ☐ Yes ☐ No
(if CLL/SLL and younger than 65) Does your patient have significant comorbidities or is your patient considered frail? ☐ Yes ☐ No

(if pcALCL) Does your patient have CD30-positive disease? ☐ Yes ☐ No

(if FL) Which of the following best applies to your patient?
☐ Medication requested is being used as first-line therapy
☐ Medication requested is being used for refractory or progressive disease
☐ Medication requested is being used as second-line or subsequent therapy
☐ other

(if HL) Is this medication being used for palliative care? ☐ Yes ☐ No

(if gastric MALT) Does your patient have recurrent or progressive disease? ☐ Yes ☐ No

(if not recurrent or progressive gastric MALT) Which of the following applies to your patient?
☐ stage I disease (tumor confined to GI tract)
☐ stage II disease (tumor extending into abdomen from primary GI site)
☐ stage II1 disease (local nodal involvement, tumor extending into abdomen from primary GI site)
☐ stage II2 disease (distant nodal involvement, tumor extending into abdomen from primary GI site)
☐ stage IIE disease (penetration of serosa to involve adjacent organs or tissues)
☐ stage IV disease (disseminated extranodal involvement, or supradiaphragmatic nodal involvement)
☐ none of the above

(if HSGDTCL) Does your patient have refractory disease? ☐ Yes ☐ No

(if high-grade B cell lymphoma) Is your patient a candidate for transplant? ☐ Yes ☐ No

(if histologic transformation) Does your patient have indolent or transformed disease? ☐ Yes ☐ No
(if histologic transformation) Has your patient received multiple lines (more than 2) of chemotherapy? ☐ Yes ☐ No

(if NON-gastric) Does your patient have refractory or progressive disease? ☐ Yes ☐ No

(if not refractory or progressive NON-gastric) Has your patient previously received any chemotherapy for this diagnosis? ☐ Yes ☐ No
(if not refractory or progressive NON-gastic) Which of the following applies to your patient?
☐ stage I (1) - II (2) disease
☐ stage IV (4) disease
☐ none of the above

(if not recurrent or progressive gastric) Is the medication requested being used as first-line therapy or as additional therapy?

☐ first-line therapy
☐ additional therapy
☐ unknown

(if not recurrent or progressive NON gastric stage I-II) Does your patient have recurrent disease? ☐ Yes ☐ No

(if MCL) Which of the following applies to your patient?
☐ relapsed, refractory or progressive disease following partial response to induction therapy
☐ Medication requested is being given in combination with acalabrutinib (Calquence) and rituximab (Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima) with previously untreated disease **(this only applies if the requested drug is bendamustine, Bendeka, or Treanda)**
☐ Medication requested is being given in combination with rituximab (Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima) as induction therapy
☐ None of the above

(if relapsed, refractory or progressive) Which of the following applies to your patient?
☐ Medication requested is being used as single-agent therapy
☐ Medication requested is being used in combination with rituximab (Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima) only
☐ Medication requested is being used in combination with rituximab (Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima) AND Velcade (bortezomib)
☐ none of the above

(if high-grad B-cell lymphoma/MM) Does your patient have relapsed, progressive, or refractory disease? ☐ Yes ☐ No

(if NMZL) Which of the following best applies to your patient?
☐ Medication requested is being used as first-line therapy
☐ Medication requested is being used as second-line or subsequent therapy
☐ None of the above/unknown

(if second-line or subsequent) Does your patient have refractory or progressive disease? ☐ Yes ☐ No

(if high-grade B-cell lymphoma, HSGDTCL, PTLD) Has your patient previously been treated with chemotherapy? ☐ Yes ☐ No

(if previous chemo) Did your patient achieve partial response with previous treatment OR does your patient have persistent or progressive disease? ☐ Yes ☐ No

(if SMZL) Which of the following applies to your patient?
☐ progressive disease after initial treatment for splenomegaly
☐ refractory or progressive disease
☐ neither of the above

(if first-line NMZL, after splenomegaly for SMZL, gastric MALT [not recurrent or progressive], non-gastric MALT [not refractory or progressive]) Will your patient also receive rituximab (Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima) while on this medication? ☐ Yes ☐ No

(if first-line FL; refractory or progressive FL, non-gastric MALT or SMZL; recurrent or progressive gastric MALT, second-line or subsequent NMZL) Will your patient also receive rituximab (Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima) or Gazyva (Obinutuzumab) while on this medication? ☐ Yes ☐ No

(if ATLL, AITL, pcALCL, DLBCL, HL, PTCL, SCLC) Does your patient have relapsed or refractory disease? ☐ Yes ☐ No

(if ATLL, pcALCL, HSGDTCL, HL age >60, MF/SS, SCLC) Will this drug be used as single agent therapy? ☐ Yes ☐ No

(if requesting bendamustine, Bendeka or Treanda for MCL and in combo with acalabrutinib and rituximab) Is the patient eligible for autologous hematopoietic stem cell transplantation (HSCT)? ☐ Yes ☐ No

Additional pertinent information: *(please include prior therapy, disease stage, performance status, and names/doses/admin schedule of any agents to be used concurrently).*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature:_____ **Date:**_____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v041525

 Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005